EyePoint Pharmaceuticals, Inc. (EYPT): Price and Financial Metrics


EyePoint Pharmaceuticals, Inc. (EYPT): $9.25

0.25 (+2.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EYPT POWR Grades


  • Value is the dimension where EYPT ranks best; there it ranks ahead of 64.93% of US stocks.
  • EYPT's strongest trending metric is Value; it's been moving down over the last 161 days.
  • EYPT ranks lowest in Sentiment; there it ranks in the 6th percentile.

EYPT Stock Summary

  • With a year-over-year growth in debt of -27.87%, EyePoint Pharmaceuticals Inc's debt growth rate surpasses merely 17.35% of about US stocks.
  • As for revenue growth, note that EYPT's revenue has grown -9.5% over the past 12 months; that beats the revenue growth of merely 13.61% of US companies in our set.
  • EyePoint Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -43.41%, greater than the shareholder yield of only 9.19% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to EyePoint Pharmaceuticals Inc, a group of peers worth examining would be PROG, SCWX, RCEL, HTGM, and MBII.
  • EYPT's SEC filings can be seen here. And to visit EyePoint Pharmaceuticals Inc's official web site, go to eyepointpharma.com.

EYPT Valuation Summary

  • In comparison to the median Healthcare stock, EYPT's price/earnings ratio is 120.82% lower, now standing at -7.6.
  • Over the past 202 months, EYPT's price/sales ratio has gone down 1296.
  • Over the past 202 months, EYPT's price/sales ratio has gone down 1296.

Below are key valuation metrics over time for EYPT.

Stock Date P/S P/B P/E EV/EBIT
EYPT 2021-08-31 8.0 2.9 -7.6 -6.4
EYPT 2021-08-30 7.4 2.7 -7.0 -5.7
EYPT 2021-08-27 7.4 2.7 -7.0 -5.7
EYPT 2021-08-26 7.3 2.7 -6.9 -5.6
EYPT 2021-08-25 7.3 2.7 -6.9 -5.6
EYPT 2021-08-24 7.4 2.7 -7.0 -5.7

EYPT Growth Metrics

    The year over year price growth rate now stands at 25.06%.
  • Its 3 year revenue growth rate is now at 227.83%.
  • Its 4 year net cashflow from operations growth rate is now at -298.73%.
EYPT's revenue has moved up $27,955,000 over the prior 33 months.

The table below shows EYPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 32.526 -27.534 -54.454
2021-06-30 39.162 -18.611 -41.56
2021-03-31 34.271 -13.189 -44.5
2020-12-31 34.437 -14.435 -45.394
2020-09-30 35.939 -31.816 -40.335
2020-06-30 22.753 -47.724 -52.181

EYPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EYPT has a Quality Grade of C, ranking ahead of 30.89% of graded US stocks.
  • EYPT's asset turnover comes in at 0.293 -- ranking 58th of 75 Measuring and Control Equipment stocks.
  • BRKR, HURC, and ONTO are the stocks whose asset turnover ratios are most correlated with EYPT.

The table below shows EYPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.293 0.804 -0.673
2021-03-31 0.322 0.818 -0.674
2020-12-31 0.433 0.831 -0.636
2020-09-30 0.480 0.870 -0.520
2020-06-30 0.301 0.862 -0.717
2020-03-31 0.319 0.871 -0.715

EYPT Price Target

For more insight on analysts targets of EYPT, see our EYPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.20 Average Broker Recommendation 1.4 (Strong Buy)

EYPT Stock Price Chart Interactive Chart >

Price chart for EYPT

EYPT Price/Volume Stats

Current price $9.25 52-week high $21.50
Prev. close $9.00 52-week low $7.30
Day low $8.96 Volume 133,959
Day high $9.49 Avg. volume 387,486
50-day MA $13.77 Dividend yield N/A
200-day MA $10.91 Market Cap 313.52M

EyePoint Pharmaceuticals, Inc. (EYPT) Company Bio


EyePoint Pharmaceuticals (formerly pSivida Corp.) develops sustained-release drug-delivery products for treating eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company was founded in 1987 and is based in Watertown, Massachusetts.


EYPT Latest News Stream


Event/Time News Detail
Loading, please wait...

EYPT Latest Social Stream


Loading social stream, please wait...

View Full EYPT Social Stream

Latest EYPT News From Around the Web

Below are the latest news stories about EyePoint Pharmaceuticals Inc that investors may wish to consider to help them evaluate EYPT as an investment opportunity.

EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements

– Updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD continue to show positive safety and efficacy results out to eight months. Further results to be presented at the February Angiogenesis 2022 virtual meeting – – Phase 2 study for EYP-1901 in wet AMD expected to initiate in Q3 2022 guided by positive Type C meeting with FDA – – Announces appointment of Michael C. Pine as Chief Corporate Development and Strategy Officer – – Record customer demand in Q4 2021 for YUTIQ® and DEXYC

Yahoo | January 10, 2022

EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer

WATERTOWN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment of Michael C. Pine as Chief Corporate Development and Strategy Officer. Mr. Pine brings over 20 years of business and corporate development expertise, leveraging experience from various roles at small and large pharmaceut

Yahoo | January 10, 2022

What You Need To Know About EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Investor Composition

A look at the shareholders of EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) can tell us which group is most powerful...

Yahoo | January 4, 2022

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of Buy from Analysts

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has earned a consensus recommendation of Buy from the five analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage []

Dakota Financial News | December 15, 2021

Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology

Founded by Renowned Experts in Ophthalmology and Immunology Launches with $10.5 million Series A Financing Led by Safar Partners to Advance Disease-Modifying Therapy for Ocular Surface Disease into the Clinic BOSTON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced its launch and the completion of a $10.5 million Series A financing led by Safar Partners with a strategic investment from a global leader in

Yahoo | December 15, 2021

Read More 'EYPT' Stories Here

EYPT Price Returns

1-mo -31.99%
3-mo -22.98%
6-mo 12.26%
1-year -6.47%
3-year -59.25%
5-year -49.45%
YTD -24.43%
2021 86.02%
2020 -57.55%
2019 -17.99%
2018 75.00%
2017 -36.84%

Continue Researching EYPT

Here are a few links from around the web to help you further your research on EyePoint Pharmaceuticals Inc's stock as an investment opportunity:

EyePoint Pharmaceuticals Inc (EYPT) Stock Price | Nasdaq
EyePoint Pharmaceuticals Inc (EYPT) Stock Quote, History and News - Yahoo Finance
EyePoint Pharmaceuticals Inc (EYPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8686 seconds.